FDA OKs 2nd Pfizer or Moderna COVID-19 booster dose for 50+ and immunocompromised demographics

On March 29th, the FDA announced that individuals over 50 can now receive a second booster dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine, should they choose to do so.
Certain immunocompromised individuals can also now receive a second booster dose of either the Pfizer-BioNTech vaccine (for 12 years and older) or the Moderna COVID-19 vaccine (for individuals 18 years and older).
The category of “certain” immunocompromised individuals includes those who have received solid organ transplants and those with health conditions that result in an “equivalent level of immunocompromise.”
The individuals specified can get their second COVID-19 booster doses a minimum of four months after they have received the first booster dose of any authorized or approved COVID-19 vaccine.
The FDA news release stated, “Emerging evidence suggests that a second booster dose of an mRNA COVID-19 vaccine improves protection against severe COVID-19 and is not associated with new safety concerns.”